| 332 | Humans |
| 217 | Male |
| 205 | Middle Aged |
| 204 | Female |
| 185 | Aged |
| 107 | Adult |
| 94 | Parkinson Disease (drug therapy) |
| 91 | Parkinson Disease (physiopathology) |
| 81 | Parkinson Disease (genetics) |
| 53 | Parkinson Disease (complications) |
| 51 | Parkinson Disease (diagnosis) |
| 47 | Aged, 80 and over |
| 40 | Treatment Outcome |
| 40 | Severity of Illness Index |
| 37 | Antiparkinson Agents (therapeutic use) |
| 35 | Follow-Up Studies |
| 35 | Double-Blind Method |
| 34 | Parkinson Disease (epidemiology) |
| 34 | Levodopa (therapeutic use) |
| 27 | Parkinson Disease (therapy) |
| 27 | Parkinson Disease (surgery) |
| 25 | Risk Factors |
| 24 | Genotype |
| 24 | Animals |
| 24 | Age of Onset |
| 23 | Disease Progression |
| 21 | Time Factors |
| 20 | Parkinson Disease (psychology) |
| 20 | Parkinson Disease (pathology) |
| 20 | Diagnosis, Differential |
| 20 | Cohort Studies |
| 19 | Neuropsychological Tests |
| 19 | Case-Control Studies |
| 18 | Prospective Studies |
| 18 | Antiparkinson Agents (adverse effects) |
| 18 | Adolescent |
| 17 | Parkinson Disease (metabolism) |
| 17 | Levodopa (adverse effects) |
| 17 | Brain (pathology) |
| 16 | Neurologic Examination |
| 16 | Genetic Predisposition to Disease |
| 15 | Retrospective Studies |
| 15 | Nerve Tissue Proteins (genetics) |
| 15 | Globus Pallidus (surgery) |
| 15 | Genetic Predisposition to Disease (genetics) |
| 14 | Neuroprotective Agents (therapeutic use) |
| 14 | Dose-Response Relationship, Drug |
| 14 | Dopamine Agonists (therapeutic use) |
| 14 | DNA Mutational Analysis |
| 13 | Parkinson Disease (etiology) |
| 13 | Mutation (genetics) |
| 13 | Gene Frequency |
| 13 | Disability Evaluation |
| 12 | Predictive Value of Tests |
| 12 | Mutation |
| 12 | Essential Tremor (genetics) |
| 12 | Dopamine (metabolism) |
| 12 | Age Factors |
| 11 | United States |
| 11 | Protein-Serine-Threonine Kinases (genetics) |
| 11 | Longitudinal Studies |
| 11 | Antiparkinson Agents (administration & dosage) |
| 10 | Polymorphism, Single Nucleotide |
| 10 | Neuroprotective Agents (pharmacology) |
| 10 | Clinical Trials as Topic |
| 10 | Brain (physiopathology) |
| 9 | Surveys and Questionnaires |
| 9 | Pedigree |
| 9 | Parkinson Disease, Secondary (chemically induced) |
| 9 | Parkinson Disease (cerebrospinal fluid) |
| 9 | Magnetic Resonance Imaging |
| 9 | Dyskinesia, Drug-Induced (etiology) |
| 9 | Cognition Disorders (etiology) |
| 9 | Alleles |
| 8 | Transcription Factors (genetics) |
| 8 | Thiophenes (administration & dosage) |
| 8 | Tetrahydronaphthalenes (administration & dosage) |
| 8 | Sex Factors |
| 8 | Polymorphism, Single Nucleotide (genetics) |
| 8 | Levodopa (administration & dosage) |
| 8 | Haplotypes |
| 8 | Genetic Variation (genetics) |
| 8 | Drug Therapy, Combination |
| 8 | Drug Administration Schedule |
| 8 | Administration, Cutaneous |
| 8 | Activities of Daily Living |
| 7 | Tremor (physiopathology) |
| 7 | Tremor (etiology) |
| 7 | Posture |
| 7 | Phenotype |
| 7 | Parkinson Disease (ethnology) |
| 7 | Neurons (metabolism) |
| 7 | Movement Disorders (therapy) |
| 7 | Essential Tremor (physiopathology) |
| 7 | Essential Tremor (epidemiology) |
| 7 | Essential Tremor (complications) |
| 7 | Dopamine Agonists (adverse effects) |
| 7 | Benzothiazoles |
| 6 | Young Adult |
| 6 | United States (epidemiology) |
| 6 | Tremor (genetics) |
| 6 | Tremor (complications) |
| 6 | Supranuclear Palsy, Progressive (physiopathology) |
| 6 | Sensitivity and Specificity |
| 6 | Selegiline (therapeutic use) |
| 6 | Risk |
| 6 | Reproducibility of Results |
| 6 | Quality of Life |
| 6 | Proportional Hazards Models |
| 6 | Polymorphism, Genetic |
| 6 | Polymerase Chain Reaction |
| 6 | Odds Ratio |
| 6 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
| 6 | Genetic Testing |
| 6 | Gait |
| 6 | Dopamine Agonists (administration & dosage) |
| 6 | Deep Brain Stimulation (adverse effects) |
| 6 | Comorbidity |
| 6 | Brain (metabolism) |
| 6 | Biomarkers (cerebrospinal fluid) |
| 5 | alpha-Synuclein (genetics) |
| 5 | Tremor (diagnosis) |
| 5 | Tomography, X-Ray Computed |
| 5 | Syndrome |
| 5 | Stereotaxic Techniques |
| 5 | Reverse Transcriptase Polymerase Chain Reaction |
| 5 | Receptors, Dopamine (metabolism) |
| 5 | Prevalence |
| 5 | Parkinson Disease (blood) |
| 5 | Movement Disorders (physiopathology) |
| 5 | Movement Disorders (drug therapy) |
| 5 | Movement Disorders (diagnosis) |
| 5 | Mice |
| 5 | Genetic Variation |
| 5 | Functional Laterality |
| 5 | European Continental Ancestry Group (genetics) |
| 5 | Essential Tremor (diagnosis) |
| 5 | Ergolines (therapeutic use) |
| 5 | Dystonia (physiopathology) |
| 5 | Dystonia (etiology) |
| 5 | Dystonia (complications) |
| 5 | Deep Brain Stimulation |
| 5 | Deep Brain Stimulation (methods) |
| 5 | Cross-Sectional Studies |
| 5 | Cognition Disorders (diagnosis) |
| 5 | Child |
| 5 | Carrier Proteins (genetics) |
| 5 | Carbidopa (therapeutic use) |
| 5 | Carbidopa (administration & dosage) |
| 5 | Basal Ganglia (physiopathology) |
| 5 | Antipsychotic Agents (therapeutic use) |
| 5 | Alzheimer Disease (cerebrospinal fluid) |
| 4 | tau Proteins (cerebrospinal fluid) |
| 4 | Ubiquitin-Protein Ligases (genetics) |
| 4 | Tremor (therapy) |
| 4 | Thiazoles (pharmacology) |
| 4 | Supranuclear Palsy, Progressive (diagnosis) |
| 4 | Subthalamic Nucleus (physiopathology) |
| 4 | Substantia Nigra (metabolism) |
| 4 | Statistics, Nonparametric |
| 4 | Single-Blind Method |
| 4 | Regression Analysis |
| 4 | Reference Values |
| 4 | Randomized Controlled Trials as Topic |
| 4 | Psychomotor Performance (physiology) |
| 4 | Postural Balance |
| 4 | Postoperative Complications (physiopathology) |
| 4 | Polymorphism, Genetic (genetics) |
| 4 | Placebos |
| 4 | Pergolide |
| 4 | Peptide Fragments (cerebrospinal fluid) |
| 4 | Parkinson Disease, Secondary (diagnosis) |
| 4 | Parkinson Disease (rehabilitation) |
| 4 | Parkinson Disease (classification) |
| 4 | Neuroprotective Agents (adverse effects) |
| 4 | Neurons (pathology) |
| 4 | Neurons (drug effects) |
| 4 | Nerve Degeneration (pathology) |
| 4 | Multiple System Atrophy (physiopathology) |
| 4 | Movement |
| 4 | Movement Disorders (genetics) |
| 4 | Movement Disorders (etiology) |
| 4 | Mice, Inbred C57BL |
| 4 | Indans (therapeutic use) |
| 4 | Genetic Association Studies |
| 4 | Gait (physiology) |
| 4 | Functional Laterality (physiology) |
| 4 | Family Health |
| 4 | Electrodes, Implanted |
| 4 | Electric Stimulation |
| 4 | Early Diagnosis |
| 4 | Dopamine (physiology) |
| 4 | Dominance, Cerebral (physiology) |
| 4 | DNA-Binding Proteins (genetics) |
| 4 | Cell Line, Tumor |
| 4 | Carbidopa (adverse effects) |
| 4 | Canada |
| 4 | Apolipoproteins E (genetics) |
| 4 | Antiparkinson Agents (pharmacology) |
| 4 | Analysis of Variance |
| 4 | Amyloid beta-Peptides (cerebrospinal fluid) |
| 4 | Alzheimer Disease (genetics) |
| 4 | Acetylcysteine (analogs & derivatives) |
| 3 | alpha-Synuclein (cerebrospinal fluid) |
| 3 | Videotape Recording |
| 3 | Tremor (surgery) |
| 3 | Tremor (drug therapy) |
| 3 | Transcription Factors (metabolism) |
| 3 | Tomography, Emission-Computed, Single-Photon |
| 3 | Tocopherols (therapeutic use) |
| 3 | Thiazoles (therapeutic use) |
| 3 | Synucleins |
| 3 | Risk Assessment |
| 3 | Reaction Time (physiology) |
| 3 | ROC Curve |
| 3 | Quality of Life (psychology) |
| 3 | Prognosis |
| 3 | Posture (physiology) |
| 3 | Postoperative Complications (diagnosis) |
| 3 | Polymorphism, Single-Stranded Conformational |
| 3 | Peripheral Nerve Injuries |
| 3 | Pergolide (adverse effects) |
| 3 | Parkinson Disease, Secondary (pathology) |
| 3 | Parkinson Disease (radiography) |
| 3 | Parkinson Disease (enzymology) |
| 3 | Pallidotomy (adverse effects) |
| 3 | Outcome Assessment (Health Care) |
| 3 | Ophthalmoplegia (diagnosis) |
| 3 | Neurons (physiology) |
| 3 | Neurodegenerative Diseases (genetics) |
| 3 | Neoplasms (epidemiology) |
| 3 | Movement Disorders (surgery) |
| 3 | Movement (physiology) |
| 3 | Motor Skills (physiology) |
| 3 | Motor Activity (physiology) |
| 3 | Motor Activity (drug effects) |
| 3 | Models, Genetic |
| 3 | Models, Animal |
| 3 | Mental Processes (physiology) |
| 3 | Memory Disorders (etiology) |
| 3 | Membrane Proteins (genetics) |
| 3 | Logistic Models |
| 3 | Lod Score |
| 3 | Linkage Disequilibrium |
| 3 | Levodopa (pharmacology) |
| 3 | Isoenzymes (genetics) |
| 3 | Huntington Disease (complications) |
| 3 | Hand (physiopathology) |
| 3 | Globus Pallidus (physiopathology) |
| 3 | Globus Pallidus (pathology) |
| 3 | Genetic Therapy (methods) |
| 3 | Genetic Markers (genetics) |
| 3 | Genetic Linkage |
| 3 | Gait Disorders, Neurologic (physiopathology) |
| 3 | Gait Disorders, Neurologic (etiology) |
| 3 | Gait Disorders, Neurologic (diagnosis) |
| 3 | European Continental Ancestry Group |
| 3 | Essential Tremor (therapy) |
| 3 | Electric Stimulation Therapy |
| 3 | Dystonia (therapy) |
| 3 | Drug Resistance |
| 3 | Dopamine Plasma Membrane Transport Proteins |
| 3 | Dopamine Agonists (pharmacology) |
| 3 | Dopamine (pharmacology) |
| 3 | Disease Models, Animal |
| 3 | Depression (etiology) |
| 3 | Dementia (pathology) |
| 3 | Deep Brain Stimulation (instrumentation) |
| 3 | DNA-Binding Proteins (metabolism) |
| 3 | Cognition |
| 3 | Chi-Square Distribution |
| 3 | Cell Line |
| 3 | Catechol O-Methyltransferase Inhibitors |
| 3 | Blotting, Western |
| 3 | Biomarkers (metabolism) |
| 3 | Biomarkers (blood) |
| 3 | Autophagy (physiology) |
| 3 | Antipsychotic Agents (adverse effects) |
| 3 | Alzheimer Disease (diagnosis) |
| 2 | tau Proteins (genetics) |
| 2 | alpha-Synuclein |
| 2 | alpha-Synuclein (metabolism) |
| 2 | alpha-Synuclein (blood) |
| 2 | Weight Loss |
| 2 | Wakefulness (physiology) |
| 2 | Vitamin E (therapeutic use) |
| 2 | Verbal Learning (physiology) |
| 2 | Ventral Thalamic Nuclei |
| 2 | Ventral Thalamic Nuclei (physiopathology) |
| 2 | Ubiquitin-Protein Ligases |
| 2 | Ubiquitin (metabolism) |
| 2 | Ubiquinone (therapeutic use) |
| 2 | Tyrosine 3-Monooxygenase (metabolism) |
| 2 | Tremor (classification) |
| 2 | Treatment Failure |
| 2 | Tourette Syndrome (history) |
| 2 | Tourette Syndrome (complications) |
| 2 | Time |
| 2 | Tics (complications) |
| 2 | Thiophenes (therapeutic use) |
| 2 | Thiophenes (adverse effects) |
| 2 | Thiazoles (adverse effects) |
| 2 | Thalamic Nuclei (surgery) |
| 2 | Tetrahydronaphthalenes (therapeutic use) |
| 2 | Tetrahydronaphthalenes (adverse effects) |
| 2 | Tetrabenazine (therapeutic use) |
| 2 | Telephone |
| 2 | Supranuclear Palsy, Progressive (etiology) |
| 2 | Subthalamic Nucleus (physiology) |
| 2 | Substantia Nigra (physiopathology) |
| 2 | Substantia Nigra (pathology) |
| 2 | Statistics as Topic |
| 2 | Societies, Medical (standards) |
| 2 | Sleep Stages |
| 2 | Sirolimus (pharmacology) |
| 2 | Sialorrhea (drug therapy) |
| 2 | Serine (genetics) |
| 2 | Serbia (epidemiology) |
| 2 | Sequence Analysis, DNA |
| 2 | Reflex Sympathetic Dystrophy (etiology) |
| 2 | Receptors, Dopamine D2 (metabolism) |
| 2 | Receptors, Dopamine (drug effects) |
| 2 | Randomized Controlled Trials as Topic (statistics & numerical data) |
| 2 | Random Allocation |
| 2 | Radiopharmaceuticals |
| 2 | RNA-Binding Proteins (genetics) |
| 2 | Quality Control |
| 2 | Putamen (physiopathology) |
| 2 | Putamen (metabolism) |
| 2 | Purines (therapeutic use) |
| 2 | Psychosurgery |
| 2 | Psychiatric Status Rating Scales |
| 2 | Protein Kinases (genetics) |
| 2 | Proteasome Inhibitors |
| 2 | Proteasome Endopeptidase Complex (metabolism) |
| 2 | Propranolol (therapeutic use) |
| 2 | Postoperative Complications (etiology) |
| 2 | Positron-Emission Tomography |
| 2 | Point Mutation |
| 2 | Point Mutation (genetics) |
| 2 | Pilot Projects |
| 2 | Physical Therapy Modalities |
| 2 | Physical Examination |
| 2 | Phosphorylation |
| 2 | Pergolide (administration & dosage) |
| 2 | Patient Selection |
| 2 | Parkinsonian Disorders (genetics) |
| 2 | Parkinsonian Disorders (epidemiology) |
| 2 | Parkinsonian Disorders (diagnosis) |
| 2 | Parkinsonian Disorders (complications) |
| 2 | Parkinson Disease, Secondary (physiopathology) |
| 2 | Parkinson Disease, Secondary (drug therapy) |
| 2 | Parkinson Disease (radionuclide imaging) |
| 2 | Parkinson Disease (prevention & control) |
| 2 | Parkinson Disease (history) |
| 2 | Pallidotomy |
| 2 | Pallidotomy (methods) |
| 2 | Oncogene Proteins (cerebrospinal fluid) |
| 2 | Occupational Exposure (adverse effects) |
| 2 | North America |
| 2 | Neurturin (genetics) |
| 2 | Neuroprotective Agents (administration & dosage) |
| 2 | Neural Pathways (physiopathology) |
| 2 | Nerve Tissue Proteins (metabolism) |
| 2 | Nerve Degeneration |
| 2 | Multivariate Analysis |
| 2 | Multiple System Atrophy (diagnosis) |
| 2 | Multiple System Atrophy (cerebrospinal fluid) |
| 2 | Movement Disorders (complications) |
| 2 | Motor Skills (drug effects) |
| 2 | Motor Activity |
| 2 | Molecular Sequence Data |
| 2 | Mobility Limitation |
| 2 | Microscopy, Electron |
| 2 | Microsatellite Repeats |
| 2 | Microelectrodes |
| 2 | Mice, Knockout |
| 2 | Mental Disorders (etiology) |
| 2 | Memory Disorders (physiopathology) |
| 2 | Memory (physiology) |
| 2 | Manganese Poisoning (physiopathology) |
| 2 | Manganese (adverse effects) |
| 2 | Linear Models |
| 2 | Ligases (genetics) |
| 2 | Lewy Bodies (pathology) |
| 2 | Iron Metabolism Disorders (genetics) |
| 2 | Iron (metabolism) |
| 2 | Intracellular Signaling Peptides and Proteins (cerebrospinal fluid) |
| 2 | Indoles (pharmacology) |
| 2 | Incidence |
| 2 | Immunohistochemistry |
| 2 | Huntington Disease (genetics) |
| 2 | Homeodomain Proteins (genetics) |
| 2 | History, 18th Century |
| 2 | Haplotypes (genetics) |
| 2 | Hallucinations (chemically induced) |
| 2 | H-Reflex (physiology) |
| 2 | Glycine (genetics) |
| 2 | Glutathione Transferase (genetics) |
| 2 | Glucosylceramidase (genetics) |
| 2 | Globus Pallidus |
| 2 | Genome-Wide Association Study |
| 2 | Genome-Wide Association Study (methods) |
| 2 | Genetic Testing (methods) |
| 2 | Gene Frequency (genetics) |
| 2 | Gait Disorders, Neurologic (drug therapy) |
| 2 | Founder Effect |
| 2 | Fluorine Radioisotopes |
| 2 | Fetal Tissue Transplantation |
| 2 | Feasibility Studies |
| 2 | Famous Persons |
| 2 | Exons (genetics) |
| 2 | Exercise (physiology) |
| 2 | Executive Function (physiology) |
| 2 | Excitatory Amino Acid Antagonists (therapeutic use) |
| 2 | Europe |
| 2 | Essential Tremor (pathology) |
| 2 | Essential Tremor (classification) |
| 2 | Ergolines (adverse effects) |
| 2 | Ergolines (administration & dosage) |
| 2 | Enzyme Inhibitors (therapeutic use) |
| 2 | Electric Stimulation Therapy (methods) |
| 2 | Dystonia (pathology) |
| 2 | Dystonia (genetics) |
| 2 | Dystonia (drug therapy) |
| 2 | Dystonia (diagnosis) |
| 2 | Dystonia (chemically induced) |
| 2 | Dyskinesia, Drug-Induced (physiopathology) |
| 2 | Dyskinesia, Drug-Induced (epidemiology) |
| 2 | Dyskinesia, Drug-Induced (drug therapy) |
| 2 | Dyskinesia, Drug-Induced (diagnosis) |
| 2 | Drug Combinations |
| 2 | Drug Combinations (therapeutic use) |
| 2 | Drug Combinations (administration & dosage) |
| 2 | Drug Administration Routes |
| 2 | Dopamine Agents (therapeutic use) |
| 2 | Dopamine (genetics) |
| 2 | Dominance, Cerebral |
| 2 | Diagnostic Imaging |
| 2 | Depressive Disorder (diagnosis) |
| 2 | Depression (diagnosis) |
| 2 | Dementia (diagnosis) |
| 2 | DNA, Mitochondrial (genetics) |
| 2 | DNA Mutational Analysis (methods) |
| 2 | Cysteine Proteinase Inhibitors (pharmacology) |
| 2 | Cues |
| 2 | Cross-Cultural Comparison |
| 2 | Corpus Striatum (physiopathology) |
| 2 | Corpus Striatum (metabolism) |
| 2 | Cognition Disorders (physiopathology) |
| 2 | Cognition Disorders (chemically induced) |
| 2 | Clozapine (therapeutic use) |
| 2 | Chromosomes, Human, Pair 2 (genetics) |
| 2 | Chromosomes, Human, Pair 17 |
| 2 | Chromosome Mapping |
| 2 | Cholinergic Antagonists (therapeutic use) |
| 2 | Child, Preschool |
| 2 | Cerebral Cortex (pathology) |
| 2 | Cerebellar Diseases (complications) |
| 2 | Cell Survival (physiology) |
| 2 | Cell Culture Techniques |
| 2 | Cell Count |
| 2 | Carbazoles (therapeutic use) |
| 2 | Bulbar Palsy, Progressive (drug therapy) |
| 2 | Bromocriptine (therapeutic use) |
| 2 | Brain Tissue Transplantation |
| 2 | Brain (radiography) |
| 2 | Brain (drug effects) |
| 2 | Brain (anatomy & histology) |
| 2 | Body Mass Index |
| 2 | Basic Helix-Loop-Helix Transcription Factors (genetics) |
| 2 | Base Sequence (genetics) |
| 2 | Basal Ganglia (pathology) |
| 2 | Autopsy |
| 2 | Autophagy (drug effects) |
| 2 | Autonomic Nervous System Diseases (etiology) |
| 2 | Austria |
| 2 | Atrophy (diagnosis) |
| 2 | Asian Continental Ancestry Group (genetics) |
| 2 | Arylamine N-Acetyltransferase (genetics) |
| 2 | Arm |
| 2 | Apoptosis (drug effects) |
| 2 | Apomorphine (therapeutic use) |
| 2 | Antiparkinson Agents (classification) |
| 2 | Antiparkinson Agents (chemistry) |
| 2 | Antioxidants (therapeutic use) |
| 2 | Amino Acid Substitution |
| 2 | Adrenal Medulla (transplantation) |
| 2 | Activities of Daily Living (classification) |
| 2 | Acetylcysteine (toxicity) |
| 2 | Acetylcysteine (pharmacology) |
| 2 | Accidental Falls (statistics & numerical data) |
| 1 | gamma-Aminobutyric Acid (metabolism) |
| 1 | fms-Like Tyrosine Kinase 3 (cerebrospinal fluid) |
| 1 | beta 2-Microglobulin |
| 1 | alpha-Synuclein (biosynthesis) |
| 1 | Writing |
| 1 | Wolff-Parkinson-White Syndrome (etiology) |
| 1 | Welding (statistics & numerical data) |
| 1 | Weights and Measures |
